On April 23, 2025, Summit Therapeutics announced that its partner Akeso achieved significant results in a clinical trial, showing that ivonescimab combined with chemotherapy improved progression-free survival in lung cancer patients over a competing treatment. This is a positive development for the company's therapeutic endeavors.